What is the share price of Krsnaa Diagnostics Ltd (KRSNAA) today?
The share price of KRSNAA as on 5th December 2025 is ₹759.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Krsnaa Diagnostics Ltd (KRSNAA) share?
The past returns of Krsnaa Diagnostics Ltd (KRSNAA) share are- Past 1 week: -5.71%
- Past 1 month: -3.20%
- Past 3 months: -8.98%
- Past 6 months: 16.69%
- Past 1 year: -24.90%
- Past 3 years: 57.32%
- Past 5 years: -23.41%
What are the peers or stocks similar to Krsnaa Diagnostics Ltd (KRSNAA)?
The peers or stocks similar to Krsnaa Diagnostics Ltd (KRSNAA) include:What is the dividend yield % of Krsnaa Diagnostics Ltd (KRSNAA) share?
The current dividend yield of Krsnaa Diagnostics Ltd (KRSNAA) is 0.36.What is the market cap of Krsnaa Diagnostics Ltd (KRSNAA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Krsnaa Diagnostics Ltd (KRSNAA) is ₹2452.04 Cr as of 5th December 2025.What is the 52 week high and low of Krsnaa Diagnostics Ltd (KRSNAA) share?
The 52-week high of Krsnaa Diagnostics Ltd (KRSNAA) is ₹1033.50 and the 52-week low is ₹625.75.What is the PE and PB ratio of Krsnaa Diagnostics Ltd (KRSNAA) stock?
The P/E (price-to-earnings) ratio of Krsnaa Diagnostics Ltd (KRSNAA) is 31.59. The P/B (price-to-book) ratio is 2.78.Which sector does Krsnaa Diagnostics Ltd (KRSNAA) belong to?
Krsnaa Diagnostics Ltd (KRSNAA) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Krsnaa Diagnostics Ltd (KRSNAA) shares?
You can directly buy Krsnaa Diagnostics Ltd (KRSNAA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Krsnaa Diagnostics Ltd
KRSNAA Share Price
759.600.49% (+3.70)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KRSNAA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KRSNAA Performance & Key Metrics
KRSNAA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.00 | 2.78 | 0.36% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
KRSNAA Company Profile
The Company provides diagnostic services. It provides radiology and pathology services for X-rays, CT scan, magnetic resonance imaging (MRI), mammography, tele reporting X-ray and all types of blood and urine investigations.
MAXHEALTH
PE Ratio
98.00
98.00
1Y Return
1.85%
1.85%
Buy Reco %
77.27
77.27
APOLLOHOSP
PE Ratio
71.61
71.61
1Y Return
0.43%
0.43%
Buy Reco %
86.21
86.21
FORTIS
PE Ratio
86.64
86.64
1Y Return
24.99%
24.99%
Buy Reco %
75.00
75.00
PE Ratio
49.80
49.80
1Y Return
47.18%
47.18%
Buy Reco %
77.78
77.78
ASTERDM
PE Ratio
6.28
6.28
1Y Return
34.87%
34.87%
Buy Reco %
100.00
100.00
KRSNAA Sentiment Analysis
KRSNAA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
KRSNAA Stock Summary · November 2025
Krsnaa Diagnostics has demonstrated resilience with an 11% year-on-year revenue growth, reaching Rs. 2,060 million, despite facing operational challenges such as prolonged receivables collection and disruptions from recent natural disasters. The company is strategically expanding its network, planning to establish 25 labs and over 500 collection centers, which is expected to enhance accessibility and drive future revenue growth, particularly in underserved regions. While the transition to new payment systems has caused temporary setbacks, investments in technology and workforce training are aimed at improving operational efficiency and patient outcomes. Krsnaa's focus on affordability and accessibility, bolstered by government initiatives, positions it well for sustained growth, with retail sales projected to contribute significantly to overall revenue in the coming years.
KRSNAA Stock Growth Drivers
KRSNAA Stock Growth Drivers
7Strong Operational Performance
Krsnaa Diagnostics has demonstrated significant operational achievements, conducting over 10 million radiology scans annually and
Commitment to Quality and Accessibility
Krsnaa Diagnostics has achieved notable milestones in quality, being the first in India to establish
KRSNAA Stock Challenges
KRSNAA Stock Challenges
6High Receivables and Working Capital Management
The company is currently facing challenges with its working capital management, as receivables are standing
Tendering Process and Competitive Challenges
There are concerns regarding the competitive nature of the tendering process, particularly in Maharashtra, where
KRSNAA Forecast
KRSNAA Forecasts
Price
Revenue
Earnings
KRSNAA Share Price Forecast
KRSNAA Share Price Forecast
2025
Current
₹755.90
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹755.90
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
KRSNAA Company Revenue Forecast
KRSNAA Company Revenue Forecast
2025
Current
₹749.17
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹749.17
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
KRSNAA Stock EPS (Earnings Per Share) Forecast
KRSNAA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹24.04
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹24.04
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
KRSNAA
KRSNAA
Income
Balance Sheet
Cash Flow
Annual Normal View
KRSNAA Income Statement
KRSNAA Income Statement
Annual Normal View
| Financial Year | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 470.36 | 506.50 | 641.89 | 749.17 | 781.32 | |||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 550.95 | |||||
| Power & Fuel Cost | 6.34 | 9.08 | 12.17 | 15.41 | ||||||
| Employee Cost | 54.15 | 74.56 | 111.47 | 136.78 | ||||||
| Selling & Administrative Expenses | 146.65 | 128.79 | 129.39 | 123.80 | ||||||
| Operating & Other expenses | 116.83 | 152.39 | 227.81 | 257.51 | ||||||
EBITDA | 146.39 | 141.68 | 161.05 | 215.67 | 230.37 | |||||
| Depreciation/Amortization | 41.39 | 53.78 | 74.55 | 88.32 | 89.88 | |||||
| PBIT | 105.00 | 87.90 | 86.50 | 127.35 | 140.49 | |||||
| Interest & Other Items | 18.49 | 7.70 | 16.49 | 24.65 | 27.43 | |||||
| PBT | 86.51 | 80.20 | 70.01 | 102.70 | 113.06 | |||||
| Taxes & Other Items | 18.12 | 18.09 | 13.17 | 25.08 | 28.52 | |||||
| Net Income | 68.39 | 62.11 | 56.84 | 77.62 | 84.54 | |||||
| EPS | 21.78 | 19.78 | 17.85 | 24.04 | 26.18 | |||||
| DPS | 2.50 | 2.75 | 2.50 | 2.75 | 2.75 | |||||
| Payout ratio | 0.11 | 0.14 | 0.14 | 0.11 | 0.11 |
KRSNAA Company Updates
FY 2026FY 2026
Investor Presentation
Nov 7PDF
Aug 11PDF
KRSNAA Stock Peers
KRSNAA Past Performance & Peer Comparison
KRSNAA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Krsnaa Diagnostics Ltd | 31.59 | 2.78 | 0.36% |
| Max Healthcare Institute Ltd | 98.00 | 11.24 | 0.14% |
| Apollo Hospitals Enterprise Ltd | 71.61 | 9.33 | 0.18% |
| Fortis Healthcare Ltd | 86.64 | 7.32 | 0.11% |
KRSNAA Stock Price Comparison
Compare KRSNAA with any stock or ETFCompare KRSNAA with any stock or ETF
KRSNAA
KRSNAA Holdings
KRSNAA Shareholdings
KRSNAA Promoter Holdings Trend
KRSNAA Promoter Holdings Trend
KRSNAA Institutional Holdings Trend
KRSNAA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KRSNAA Shareholding Pattern
KRSNAA Shareholding Pattern
KRSNAA Shareholding History
KRSNAA Shareholding History
Foreign Institutions
Mutual Funds Invested in KRSNAA
Mutual Funds Invested in KRSNAA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Krsnaa Diagnostics Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3124% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months -0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/33 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2283% | Percentage of the fund’s portfolio invested in the stock 2.91% | Change in the portfolio weight of the stock over the last 3 months -0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/51 (-7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1906% | Percentage of the fund’s portfolio invested in the stock 0.31% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 96/105 (-6) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing KRSNAA stock
smallcases containing KRSNAA stock
Looks like this stock is not in any smallcase yet.
KRSNAA Events
KRSNAA Events
KRSNAA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KRSNAA Dividend Trend
No dividend trend available
KRSNAA Upcoming Dividends
KRSNAA Upcoming Dividends
No upcoming dividends are available
KRSNAA Past Dividends
KRSNAA Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹2.75
Dividend/Share
₹2.75
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 13, 2024
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹2.75
Dividend/Share
₹2.75
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 15, 2022
KRSNAA Stock News & Opinions
KRSNAA Stock News & Opinions
Articles & Videos
Earnings
Krsnaa Diagnostics consolidated net profit rises 22.19% in the September 2025 quarter
Net profit of Krsnaa Diagnostics rose 22.19% to Rs 23.95 crore in the quarter ended September 2025 as against Rs 19.60 crore during the previous quarter ended September 2024. Sales rose 10.55% to Rs 205.99 crore in the quarter ended September 2025 as against Rs 186.34 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales205.99186.34 11 OPM %28.7226.51 - PBDT55.1547.61 16 PBT31.5625.40 24 NP23.9519.60 22 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Krsnaa Diagnostics to table results
Krsnaa Diagnostics will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Krsnaa Diagnostics schedules AGM
Krsnaa Diagnostics announced that the Annual General Meeting(AGM) of the company will be held on 25 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Krsnaa Diagnostics consolidated net profit rises 14.51% in the June 2025 quarter
Net profit of Krsnaa Diagnostics rose 14.51% to Rs 20.52 crore in the quarter ended June 2025 as against Rs 17.92 crore during the previous quarter ended June 2024. Sales rose 13.36% to Rs 192.98 crore in the quarter ended June 2025 as against Rs 170.23 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales192.98170.23 13 OPM %26.6325.06 - PBDT49.0544.67 10 PBT27.4223.20 18 NP20.5217.92 15 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Krsnaa Diagnostics to convene board meeting
Krsnaa Diagnostics will hold a meeting of the Board of Directors of the Company on 11 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Board of Krsnaa Diagnostics recommends final dividend
Krsnaa Diagnostics announced that the Board of Directors of the Company at its meeting held on 12 May 2025, inter alia, have recommended the final dividend of Rs 2.75 per equity Share (i.e. 55%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Krsnaa Diagnostics consolidated net profit rises 10.41% in the March 2025 quarter
Net profit of Krsnaa Diagnostics rose 10.41% to Rs 20.68 crore in the quarter ended March 2025 as against Rs 18.73 crore during the previous quarter ended March 2024. Sales rose 11.91% to Rs 186.08 crore in the quarter ended March 2025 as against Rs 166.28 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.54% to Rs 77.61 crore in the year ended March 2025 as against Rs 56.84 crore during the previous year ended March 2024. Sales rose 15.74% to Rs 717.16 crore in the year ended March 2025 as against Rs 619.63 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales186.08166.28 12 717.16619.63 16 OPM %28.4726.28 -26.5123.28 - PBDT50.5640.72 24 191.01144.55 32 PBT28.6122.61 27 102.6970.01 47 NP20.6818.73 10 77.6156.84 37 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Krsnaa Diagnostics schedules board meeting
Krsnaa Diagnostics will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Krsnaa Diagnostics receives affirmation in credit ratings for bank facilities
Krsnaa Diagnostics announced that ICRA has reaffirmed a long-term rating of ICRA A (Stable) (pronounced ICRA A) for Rs 111.88 crore and a short-term rating of ICRA A1 (pronounced ICRA A One) for Rs 112.00 crore Bank Loan Facilities. The Outlook on the long-term rating is Stable.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Krsnaa Diagnostics consolidated net profit rises 49.73% in the December 2024 quarter
Net profit of Krsnaa Diagnostics rose 49.73% to Rs 19.42 crore in the quarter ended December 2024 as against Rs 12.97 crore during the previous quarter ended December 2023. Sales rose 10.23% to Rs 174.51 crore in the quarter ended December 2024 as against Rs 158.32 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales174.51158.32 10 OPM %25.8323.62 - PBDT48.1837.33 29 PBT25.4816.10 58 NP19.4212.97 50 Powered by Capital Market - Live
9 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant